M&A Deal Summary

Genexine Acquires Argos Therapeutics

On February 13, 2019, Genexine acquired life science company Argos Therapeutics for 11M USD

Acquisition Highlights
  • This is Genexine’s 1st transaction in the Life Science sector.
  • This is Genexine’s largest (disclosed) transaction.
  • This is Genexine’s 1st transaction in the United States.
  • This is Genexine’s 1st transaction in North Carolina.

M&A Deal Summary
Date 2019-02-13
Target Argos Therapeutics
Sector Life Science
Buyer(s) Genexine
Deal Type Add-on Acquisition
Deal Value 11M USD

Target

Argos Therapeutics

Durham, North Carolina, United States
Argos Therapeutics, Inc. is a developer of therapeutic vaccines against carcinoma, melanoma, leukemia and HIV. Argos Therapeutics, Inc. was formed in 1997 and is headquartered in Durham, North Carolina.

Search 198,242 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Genexine

Seongnam, South Korea
Category Company
Founded 1999
Sector Life Science
Employees123
Revenue 6.3B KRW (2012)
DESCRIPTION

Genexine is a clinical-stage biotechnology company focused on the development and commercialization of innovative immunotherapeutics and next-generation novel long-acting biologics. Genexine is based in Gyeonggi-do, South Korea. Genexine was founded in 1999 and is based in Seongnam, South Korea.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (North Carolina) 1 of 1
Country (United States) 1 of 1
Year (2019) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal